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Genomic DNA copy number alterations are key genetic events in
the development and progression of human cancers. Here we
report a genome-wide microarray comparative genomic hybrid-
ization (array CGH) analysis of DNA copy number variation in
a series of primary human breast tumors. We have profiled DNA
copy number alteration across 6,691 mapped human genes, in 44
predominantly advanced, primary breast tumors and 10 breast
cancer cell lines. While the overall patterns of DNA amplification
and deletion corroborate previous cytogenetic studies, the high-
resolution (gene-by-gene) mapping of amplicon boundaries and
the quantitative analysis of amplicon shape provide significant
improvement in the localization of candidate oncogenes. Parallel
microarray measurements of mRNA levels reveal the remarkable
degree to which variation in gene copy number contributes to
variation in gene expression in tumor cells. Specifically, we find
that 62% of highly amplified genes show moderately or highly
elevated expression, that DNA copy number influences gene ex-
pression across a wide range of DNA copy number alterations
(deletion, low-, mid- and high-level amplification), that on average,
a 2-fold change in DNA copy number is associated with a corre-
sponding 1.5-fold change in mRNA levels, and that overall, at least
12% of all the variation in gene expression among the breast
tumors is directly attributable to underlying variation in gene copy
number. These findings provide evidence that widespread DNA
copy number alteration can lead directly to global deregulation of
gene expression, which may contribute to the development or
progression of cancer.
Conventional cytogenetic techniques, including comparativegenomic hybridization (CGH) (1), have led to the identifi-
cation of a number of recurrent regions of DNA copy number
alteration in breast cancer cell lines and tumors (2–4). While
some of these regions contain known or candidate oncogenes
[e.g., FGFR1 (8p11), MYC (8q24), CCND1 (11q13), ERBB2
(17q12), and ZNF217 (20q13)] and tumor suppressor genes
[RB1 (13q14) and TP53 (17p13)], the relevant gene(s) within
other regions (e.g., gain of 1q, 8q22, and 17q22–24, and loss of
8p) remain to be identified. A high-resolution genome-wide
map, delineating the boundaries of DNA copy number alter-
ations in tumors, should facilitate the localization and identifi-
cation of oncogenes and tumor suppressor genes in breast
cancer. In this study, we have created such a map, using
array-based CGH (5–7) to profile DNA copy number alteration
in a series of breast cancer cell lines and primary tumors.
An unresolved question is the extent to which the widespread
DNA copy number changes that we and others have identified
in breast tumors alter expression of genes within involved
regions. Because we had measured mRNA levels in parallel in
the same samples (8), using the same DNA microarrays, we had
an opportunity to explore on a genomic scale the relationship
between DNA copy number changes and gene expression. From
this analysis, we have identified a significant impact of wide-
spread DNA copy number alteration on the transcriptional
programs of breast tumors.
Materials and Methods
Tumors and Cell Lines. Primary breast tumors were predominantly
large (3 cm), intermediate-grade, infiltrating ductal carcino-
mas, with more than 50% being lymph node positive. The
fraction of tumor cells within specimens averaged at least 50%.
Details of individual tumors have been published (8, 9), and
are summarized in Table 1, which is published as supporting
information on the PNAS web site, www.pnas.org. Breast cancer
cell lines were obtained from the American Type Culture
Collection. Genomic DNA was isolated either using Qiagen
genomic DNA columns, or by phenolchloroform extraction
followed by ethanol precipitation.
DNA Labeling and Microarray Hybridizations. Genomic DNA label-
ing and hybridizations were performed essentially as described
in Pollack et al. (7), with slight modifications. Two micrograms
of DNA was labeled in a total volume of 50 microliters and the
volumes of all reagents were adjusted accordingly. ‘‘Test’’ DNA
(from tumors and cell lines) was fluorescently labeled (Cy5) and
hybridized to a human cDNA microarray containing 6,691
different mapped human genes (i.e., UniGene clusters). The
‘‘reference’’ (labeled with Cy3) for each hybridization was nor-
mal female leukocyte DNA from a single donor. The fabrication
of cDNA microarrays and the labeling and hybridization of
mRNA samples have been described (8).
Data Analysis and Map Positions. Hybridized arrays were scanned
on a GenePix scanner (Axon Instruments, Foster City, CA), and
fluorescence ratios (testreference) calculated using SCANALYZE
software (available at http:rana.lbl.gov). Fluorescence ratios
were normalized for each array by setting the average log
fluorescence ratio for all array elements equal to 0. Measure-
ments with fluorescence intensities more than 20% above back-
ground were considered reliable. DNA copy number profiles
that deviated significantly from background ratios measured in
normal genomic DNA control hybridizations were interpreted as
evidence of real DNA copy number alteration (see Estimating
Significance of Altered Fluorescence Ratios in the supporting
information). When indicated, DNA copy number profiles are
displayed as a moving average (symmetric 5-nearest neighbors).
Map positions for arrayed human cDNAs were assigned by
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identifying the starting position of the best and longest match of
any DNA sequence represented in the corresponding UniGene
cluster (10) against the ‘‘Golden Path’’ genome assembly
(http:genome.ucsc.edu; Oct 7, 2000 Freeze). For UniGene
clusters represented by multiple arrayed elements, mean fluo-
rescence ratios (for all elements representing the same UniGene
cluster) are reported. For mRNA measurements, f luorescence
ratios are ‘‘mean-centered’’ (i.e., reported relative to the mean
ratio across the 44 tumor samples). The data set described here
can be accessed in its entirety in the supporting information.
Results
We performed CGH on 44 predominantly locally advanced,
primary breast tumors and 10 breast cancer cell lines, using
cDNA microarrays containing 6,691 different mapped human
genes (Fig. 1a; also see Materials and Methods for details of
microarray hybridizations). To take full advantage of the im-
proved spatial resolution of array CGH, we ordered (fluores-
cence ratios for) the 6,691 cDNAs according to the ‘‘Golden
Path’’ (http:genome.ucsc.edu) genome assembly of the draft
human genome sequences (11). In so doing, arrayed cDNAs not
only themselves represent genes of potential interest (e.g.,
candidate oncogenes within amplicons), but also provide precise
genetic landmarks for chromosomal regions of amplification and
deletion. Parallel analysis of DNA from cell lines containing
different numbers of X chromosomes (Fig. 1b), as we did before
(7), demonstrated the sensitivity of our method to detect single-
copy loss (45, XO), and 1.5- (47,XXX), 2- (48,XXXX), or
2.5-fold (49,XXXXX) gains (also see Fig. 5, which is published
as supporting information on the PNAS web site). Fluorescence
ratios were linearly proportional to copy number ratios, which
were slightly underestimated, in agreement with previous ob-
servations (7). Numerous DNA copy number alterations were
evident in both the breast cancer cell lines and primary tumors
(Fig. 1a), detected in the tumors despite the presence of euploid
non-tumor cell types; the magnitudes of the observed changes
were generally lower in the tumor samples. DNA copy-number
alterations were found in every cancer cell line and tumor, and
on every human chromosome in at least one sample. Recurrent
regions of DNA copy number gain and loss were readily iden-
tifiable. For example, gains within 1q, 8q, 17q, and 20q were
observed in a high proportion of breast cancer cell linestumors
(90%69%, 100%47%, 100%60%, and 90%44%, respective-
ly), as were losses within 1p, 3p, 8p, and 13q (80%24%,
80%22%, 80%22%, and 70%18%, respectively), consistent
with published cytogenetic studies (refs. 2–4; a complete listing
of gainslosses is provided in Tables 2 and 3, which are published
as supporting information on the PNAS web site). The total
Fig. 1. Genome-wide measurement of DNA copy number alteration by array CGH. (a) DNA copy number profiles are illustrated for cell lines containing different
numbers of X chromosomes, for breast cancer cell lines, and for breast tumors. Each row represents a different cell line or tumor, and each column represents
one of 6,691 different mapped human genes present on the microarray, ordered by genome map position from 1pter through Xqter. Moving average (symmetric
5-nearest neighbors) fluorescence ratios (testreference) are depicted using a log2-based pseudocolor scale (indicated), such that red luminescence reflects
fold-amplification, green luminescence reflects fold-deletion, and black indicates no change (gray indicates poorly measured data). (b) Enlarged view of DNA
copy number profiles across the X chromosome, shown for cell lines containing different numbers of X chromosomes.
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number of genomic alterations (gains and losses) was found to
be significantly higher in breast tumors that were high grade (P 
0.008), consistent with published CGH data (3), estrogen recep-
tor negative (P  0.04), and harboring TP53 mutations (P 
0.0006) (see Table 4, which is published as supporting informa-
tion on the PNAS web site).
The improved spatial resolution of our array CGH analysis is
illustrated for chromosome 8, which displayed extensive DNA
copy number alteration in our series. A detailed view of the
variation in the copy number of 241 genes mapping to chromo-
some 8 revealed multiple regions of recurrent amplification;
each of these potentially harbors a different known or previously
uncharacterized oncogene (Fig. 2a). The complexity of amplicon
structure is most easily appreciated in the breast cancer cell line
SKBR3. Although a conventional CGH analysis of 8q in SKBR3
identified only two distinct regions of amplification (12), we
observed three distinct regions of high-level amplification (la-
beled 1–3 in Fig. 2b). For each of these regions we can define the
boundaries of the interval recurrently amplified in the tumors we
examined; in each case, known or plausible candidate oncogenes
can be identified (a description of these regions, as well as the
recurrently amplified regions on chromosomes 17 and 20, can be
found in Figs. 6 and 7, which are published as supporting
information on the PNAS web site).
For a subset of breast cancer cell lines and tumors (4 and 37,
respectively), and a subset of arrayed genes (6,095), mRNA
levels were quantitatively measured in parallel by using cDNA
microarrays (8). The parallel assessment of mRNA levels is
useful in the interpretation of DNA copy number changes. For
example, the highly amplified genes that are also highly ex-
pressed are the strongest candidate oncogenes within an ampli-
con. Perhaps more significantly, our parallel analysis of DNA
copy number changes and mRNA levels provides us the oppor-
tunity to assess the global impact of widespread DNA copy
number alteration on gene expression in tumor cells.
A strong influence of DNA copy number on gene expression
is evident in an examination of the pseudocolor representations
Fig. 2. DNA copy number alteration across chromosome 8 by array CGH. (a) DNA copy number profiles are illustrated for cell lines containing different numbers
of X chromosomes, for breast cancer cell lines, and for breast tumors. Breast cancer cell lines and tumors are separately ordered by hierarchical clustering to
highlight recurrent copy number changes. The 241 genes present on the microarrays and mapping to chromosome 8 are ordered by position along the
chromosome. Fluorescence ratios (testreference) are depicted by a log2 pseudocolor scale (indicated). Selected genes are indicated with color-coded text (red,
increased; green, decreased; black, no change; gray, not well measured) to reflect correspondingly altered mRNA levels (observed in the majority of the subset
of samples displaying the DNA copy number change). The map positions for genes of interest that are not represented on the microarray are indicated in the
row above those genes represented on the array. (b) Graphical display of DNA copy number profile for breast cancer cell line SKBR3. Fluorescence ratios
(tumornormal) are plotted on a log2 scale for chromosome 8 genes, ordered along the chromosome.
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of DNA copy number and mRNA levels for genes on chromo-
some 17 (Fig. 3). The overall patterns of gene amplification and
elevated gene expression are quite concordant; i.e., a significant
fraction of highly amplified genes appear to be correspondingly
highly expressed. The concordance between high-level amplifi-
cation and increased gene expression is not restricted to chro-
mosome 17. Genome-wide, of 117 high-level DNA amplifica-
tions (fluorescence ratios 4, and representing 91 different
genes), 62% (representing 54 different genes; see Table 5, which
is published as supporting information on the PNAS web site)
are found associated with at least moderately elevated mRNA
levels (mean-centered fluorescence ratios 2), and 42% (rep-
resenting 36 different genes) are found associated with compa-
rably highly elevated mRNA levels (mean-centered fluorescence
ratios 4).
To determine the extent to which DNA deletion and lower-
level amplification (in addition to high-level amplification) are
also associated with corresponding alterations in mRNA levels,
we performed three separate analyses on the complete data set
(4 cell lines and 37 tumors, across 6,095 genes). First, we
determined the average mRNA levels for each of five classes
of genes, representing DNA deletion, no change, and low-,
medium-, and high-level amplification (Fig. 4a). For both the
breast cancer cell lines and tumors, average mRNA levels
tracked with DNA copy number across all five classes, in a
statistically significant fashion (P values for pair-wise Student’s
t tests comparing adjacent classes: cell lines, 4  1049, 1  1049,
5  105, 1  102; tumors, 1  1043, 1  10214, 5  1041,
1  104). A linear regression of the average log(DNA copy
number), for each class, against average log(mRNA level)
demonstrated that on average, a 2-fold change in DNA copy
number was accompanied by 1.4- and 1.5-fold changes in mRNA
level for the breast cancer cell lines and tumors, respectively (Fig.
4a, regression line not shown). Second, we characterized the
distribution of the 6,095 correlations between DNA copy num-
ber and mRNA level, each across the 37 tumor samples (Fig. 4b).
The distribution of correlations forms a normal-shaped curve,
but with the peak markedly shifted in the positive direction from
zero. This shift is statistically significant, as evidenced in a plot
of observed vs. expected correlations (Fig. 4c), and reflects a
pervasive global influence of DNA copy number alterations on
gene expression. Notably, the highest correlations between DNA
copy number and mRNA level (the right tail of the distribution
in Fig. 4b) comprise both amplified and deleted genes (data not
shown). Third, we used a linear regression model to estimate the
fraction of all variation measured in mRNA levels among the 37
Fig. 3. Concordance between DNA copy number and gene expression across chromosome 17. DNA copy number alteration (Upper) and mRNA levels (Lower)
are illustrated for breast cancer cell lines and tumors. Breast cancer cell lines and tumors are separately ordered by hierarchical clustering (Upper), and the
identical sample order is maintained (Lower). The 354 genes present on the microarrays and mapping to chromosome 17, and for which both DNA copy number
and mRNA levels were determined, are ordered by position along the chromosome; selected genes are indicated in color-coded text (see Fig. 2 legend).
Fluorescence ratios (testreference) are depicted by separate log2 pseudocolor scales (indicated).
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tumors that could be attributed to underlying variation in DNA
copy number. From this analysis, we estimate that, overall, about
7% of all of the observed variation in mRNA levels can be
explained directly by variation in copy number of the altered
genes (Fig. 4d). We can reduce the effects of experimental
measurement error on this estimate by using only that fraction
of the data most reliably measured (fluorescence intensity
background 3); using that data, our estimate of the percent
variation in mRNA levels directly attributed to variation in gene
copy number increases to 12% (Fig. 4d). This still undoubtedly
represents a significant underestimate, as the observed variation
in global gene expression is affected not only by true variation in
the expression programs of the tumor cells themselves, but also
by the variable presence of non-tumor cell types within clinical
samples.
Discussion
This genome-wide, array CGH analysis of DNA copy number
alteration in a series of human breast tumors demonstrates the
usefulness of defining amplicon boundaries at high resolution
(gene-by-gene), and quantitatively measuring amplicon shape, to
assist in locating and identifying candidate oncogenes. By ana-
lyzing mRNA levels in parallel, we have also discovered that
changes in DNA copy number have a large, pervasive, direct
effect on global gene expression patterns in both breast cancer
cell lines and tumors. Although the DNA microarrays used in our
analysis may display a bias toward characterized andor highly
expressed genes, because we are examining such a large fraction
of the genome (approximately 20% of all human genes), and
because, as detailed above, we are likely underestimating the
contribution of DNA copy number changes to altered gene
expression, we believe our findings are likely to be generalizable
(but would nevertheless still be remarkable if only applicable to
this set of 6,100 genes).
In budding yeast, aneuploidy has been shown to result in
chromosome-wide gene expression biases (13). Two recent
studies have begun to examine the global relationship between
DNA copy number and gene expression in cancer cells. In
agreement with our findings, Phillips et al. (14) have shown that
with the acquisition of tumorigenicity in an immortalized pros-
tate epithelial cell line, new chromosomal gains and losses
resulted in a statistically significant respective increase and
decrease in the average expression level of involved genes. In
contrast, Platzer et al. (15) recently reported that in metastatic
colon tumors only 4% of genes within amplified regions were
found more highly (2-fold) expressed, when compared with
normal colonic epithelium. This report differs substantially from
our finding that 62% of highly amplified genes in breast cancer
exhibit at least 2-fold increased expression. These contrasting
findings may reflect methodological differences between the
Fig. 4. Genome-wide influence of DNA copy number alterations on mRNA levels. (a) For breast cancer cell lines (gray) and tumor samples (black), both
mean-centered mRNA fluorescence ratio (log2 scale) quartiles (box plots indicate 25th, 50th, and 75th percentile) and averages (diamonds; Y-value error bars
indicate standard errors of the mean) are plotted for each of five classes of genes, representing DNA deletion (tumornormal ratio  0.8), no change (0.8–1.2),
low- (1.2–2), medium- (2–4), and high-level (4) amplification. P values for pair-wise Student’s t tests, comparing averages between adjacent classes (moving
left to right), are 4  1049, 1  1049, 5  105, 1  102 (cell lines), and 1  1043, 1  10214, 5  1041, 1  104 (tumors). (b) Distribution of correlations between
DNA copy number and mRNA levels, for 6,095 different human genes across 37 breast tumor samples. (c) Plot of observed versus expected correlation coefficients.
The expected values were obtained by randomization of the sample labels in the DNA copy number data set. The line of unity is indicated. (d) Percent variance
in gene expression (among tumors) directly explained by variation in gene copy number. Percent variance explained (black line) and fraction of data retained
(gray line) are plotted for different fluorescence intensitybackground (a rough surrogate for signalnoise) cutoff values. Fraction of data retained is relative
to the 1.2 intensitybackground cutoff. Details of the linear regression model used to estimate the fraction of variation in gene expression attributable to
underlying DNA copy number alteration can be found in the supporting information (see Estimating the Fraction of Variation in Gene Expression Attributable
to Underlying DNA Copy Number Alteration).
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studies. For example, the study of Platzer et al. (15) may have
systematically under-measured gene expression changes. In this
regard it is remarkable that only 14 transcripts of many thousand
residing within unamplified chromosomal regions were found to
exhibit at least 4-fold altered expression in metastatic colon
cancer. Additionally, their reliance on lower-resolution chromo-
somal CGH may have resulted in poorly delimiting the bound-
aries of high-complexity amplicons, effectively overcalling re-
gions with amplification. Alternatively, the contrasting findings
for amplified genes may represent real biological differences
between breast and metastatic colon tumors; resolution of this
issue will require further studies.
Our finding that widespread DNA copy number alteration has
a large, pervasive and direct effect on global gene expression
patterns in breast cancer has several important implications.
First, this finding supports a high degree of copy number-
dependent gene expression in tumors. Second, it suggests that
most genes are not subject to specific autoregulation or dosage
compensation. Third, this finding cautions that elevated expres-
sion of an amplified gene cannot alone be considered strong
independent evidence of a candidate oncogene’s role in tumor-
igenesis. In our study, fully 62% of highly amplified genes
demonstrated moderately or highly elevated expression. This
highlights the importance of high-resolution mapping of ampli-
con boundaries and shape [to identify the ‘‘driving’’ gene(s)
within amplicons (16)], on a large number of samples, in addition
to functional studies. Fourth, this finding suggests that analyzing
the genomic distribution of expressed genes, even within existing
microarray gene expression data sets, may permit the inference
of DNA copy number aberration, particularly aneuploidy (where
gene expression can be averaged across large chromosomal
regions; see Fig. 3 and supporting information). Fifth, this
finding implies that a substantial portion of the phenotypic
uniqueness (and by extension, the heterogeneity in clinical
behavior) among patients’ tumors may be traceable to underly-
ing variation in DNA copy number. Sixth, this finding supports
a possible role for widespread DNA copy number alteration in
tumorigenesis (17, 18), beyond the amplification of specific
oncogenes and deletion of specific tumor suppressor genes.
Widespread DNA copy number alteration, and the concomitant
widespread imbalance in gene expression, might disrupt critical
stochiometric relationships in cell metabolism and physiology
(e.g., proteosome, mitotic spindle), possibly promoting further
chromosomal instability and directly contributing to tumor
development or progression. Finally, our findings suggest the
possibility of cancer therapies that exploit specific or global
imbalances in gene expression in cancer.
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